智通财经APP获悉，联交所最新资料显示，2月2日，The Goldman Sachs Group, Inc.增持爱康医疗 (01789)2万股，每股作价5.69港元，总金额为11.38万港元。增持后最新持股数目约为5620.87万股，最新 持股比例为5%。 ...

Core Viewpoint - The company has focused on a core strategic direction of "rapamycin drug balloons + intravascular imaging + special balloons + vascular reduction" in its cardiovascular division over the past five years, with a key real-world study confirming the leading nature of this technology route [1] Group 1 - A significant real-world study presented at the 2025 TCT Global Interventional Cardiology Conference demonstrated that rapamycin drug balloons achieved non-inferior results compared to stents in a population with over 60% complex lesions and large vessel primary lesions [1] - The study results validate the industry trend of rapamycin drug balloons replacing traditional stents [1] - The company has made systematic arrangements for years, locking in on the rapamycin drug balloon direction while simultaneously developing supporting intravascular imaging and special balloons, creating a comprehensive advantage of "technology route + product matrix + ecological synergy" [1] Group 2 - In product development, the company has a richer new product layout in the coronary artery field compared to its peers, including future vascular reduction products that will be paired with drug balloons [1] - The medical device industry has transitioned from "imitation and following" to "original competition," necessitating deep clinical cooperation with hospitals for future research and development [1] - The company has established clinical cooperation projects with several top-ranked hospitals in the domestic coronary artery industry, maintaining a leading position in original research and development [1]

Core Viewpoint - The company has a clear ability to anticipate fluctuations in raw material prices and has proactively completed raw material reserves for the first quarter of 2026 to lock in production costs [1] Group 1: Raw Material Strategy - The company will continue to adhere to a procurement strategy that emphasizes market trends over price, engaging in wave-based operations [1] - During periods of low prices for bulk trading raw materials for health protective gloves, the company will decisively purchase in excess to prepare for future price increases [1] - When anticipating a continuous decline in bulk trading raw material prices, the company will adopt a just-in-time purchasing approach to minimize costs and maintain a competitive edge [1]

祥生医疗公告，公司2025年前三季度每股现金红利为0.30元。股权登记日为2026年2月11日，除权 （息）日为2026年2月12日，现金红利发放日为2026年2月12日。本次利润分配以方案实施前的公司总股 本1.12亿股为基数，共计派发现金红利3363.77万元。 ...

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd. (referred to as "Tuomai Medical"), has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The product represents a significant advancement in the company's medical device offerings [1]

赛诺医疗(688108.SH)公告称，公司收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册 证》，注册证编号为国械注准20263130263，产品名称为药物洗脱支架系统。该产品适用于改善局部缺 血型心脏病患者的血管狭窄症状，有效期至2031年2月2日。这是赛诺医疗自主研发并生产的冠脉支架类 产品，获批将进一步丰富公司的产品组合，提升核心竞争力。但该产品后续尚需进行医疗器械生产许可 变更后方可生产，实际销售情况取决于市场推广效果，对公司未来业绩的具体影响尚无法预测。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The core point of the article is that Shanghai MicroPort MedBot (Group) Co., Ltd.'s wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its product "Polyvinyl Alcohol Embolization Microspheres" [1] Group 2 - The product "Polyvinyl Alcohol Embolization Microspheres" is a new medical device aimed at enhancing treatment options in the healthcare sector [1]

赛诺医疗公告，近日，公司收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》。产品 名称为药物洗脱支架系统，适用于改善局部缺血型心脏病患者的血管狭窄症状。该产品为赛诺医疗自主 研发并生产，其获批将丰富公司产品组合，满足市场需求，提升核心竞争力。 ...

结构及组成：药物洗脱支架系统由药物涂层支架和快速交换球囊导管输送系统组成。药物涂层支架以 L605钴铬合金支架为基体，表面涂覆底部涂层和含药高分子涂层。底部涂层材料为聚甲基丙烯酸丁酯 （PBuMA），该涂层不可降解；药物涂层由雷帕霉素药物和聚乳酸-羟基乙酸（PLGA）组成，为可降 解涂层。支架药物剂量密度为1.20μg/mm2；载药量为59μg～324μg。输送系统由TIP头、球囊、 Marker、球囊内管、球囊外管和手柄组成。产品经过电子束灭菌，一次性使用。货架有效期18个月。 适用范围：该产品适用于参考1.血管直径为2.25～4.00mm，适用的病变长度≤40mm；2.参考血管直径为 4.50～5.00mm，适用的病变长度≤30mm；用于改善局部缺血型心脏病患者的血管狭窄症状。 格隆汇2月4日丨赛诺医疗(688108.SH)公布，近日，公司收到国家药品监督管理局颁发的《中华人民共 和国医疗器械注册证》，产品名称：药物洗脱支架系统，注册证编号：国械注准20263130263。 本次获得《医疗器械注册证》的药物洗脱支架系统，是由我公司自主研发并进行生产的一款冠脉支架类 产品。该产品是一个预装的药物洗脱支架系统 ...

Core Viewpoint - 康泰医学预计2025年度归母净利润将亏损1700万元至3300万元，相较于上年同期的亏损7790万元有所改善 [2] Financial Performance - 2025年度预计计提存货减值准备金额较上年减少，尽管相关计提对净利润的影响尚未完全消除 [2] - 预计2025年净利润较上年同期减亏，显示出公司在财务管理上的改善 [2]